title: Antiblastic treatment of haematological malignancies during pregnancy: a crucial decision.
abstract: Antiblastic treatment of hematological malignancies during pregnancy poses a number of issues related to the curability of the maternal disease, the need of a prompt treatment and the potential toxicity of chemotherapy for the fetus. Here we report the results of a systematic literature search about the management of the most frequent hematological malignancies that may occur during pregnancy, focusing on specific issues related to gestational age at diagnosis, fetal toxicity and efficacy on the maternal side. The standard approach in non-pregnant women is illustrated as reference.
authors.affiliation: Department of Medical Oncology, National Cancer Institute, Aviano (PN), Italy. mmichieli@cro.it
authors.forename: M
authors.initials: M
authors.lastname: Michieli
authors.forename: F A
authors.initials: FA
authors.lastname: Peccatori
authors.forename: A
authors.initials: A
authors.lastname: Lleshi
authors.forename: L
authors.initials: L
authors.lastname: Del Pup
authors.forename: D
authors.initials: D
authors.lastname: Valente
authors.forename: M
authors.initials: M
authors.lastname: Rupolo
authors.forename: U
authors.initials: U
authors.lastname: Tirelli
authors.forename: M
authors.initials: M
authors.lastname: Berretta
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents